Along with insulin, therapeutic replacement of amylin, as originally suggested [34], is nowadays recommended for a more tight control of glycemia in individuals with either type 1 or type 2 diabetes mellitus (T1DM or T2DM, respectively) [10,33,35–41]. The gene discussed is IAPP; the disease is type 1 diabetes mellitus.